Emerging therapeutic targets for neuromyelitis optica spectrum disorder
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging therapeutic targets for neuromyelitis optica spectrum disorder
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2020-02-19
DOI
10.1080/14728222.2020.1732927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
- (2019) Rita Kansal et al. Science Translational Medicine
- CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
- (2019) Lukmanee Tradtrantip et al. Journal of Neuroinflammation
- Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica
- (2019) Mark Lipphardt et al. JOURNAL OF CLINICAL APHERESIS
- Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica
- (2019) John Soltys et al. JOURNAL OF CLINICAL INVESTIGATION
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- (2019) Sean J. Pittock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
- (2019) Irati Zubizarreta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Developing therapeutic strategies to promote myelin repair in multiple sclerosis
- (2019) Laura E. Baldassari et al. Expert Review of Neurotherapeutics
- Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
- (2019) Tianjiao Duan et al. Acta Neuropathologica Communications
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Next-generation Fc receptor–targeting biologics for autoimmune diseases
- (2019) Adrian W. Zuercher et al. AUTOIMMUNITY REVIEWS
- Experimental animal models of aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorders: progress and shortcomings
- (2019) Tianjiao Duan et al. BRAIN PATHOLOGY
- Compendium of current complement therapeutics
- (2019) Wioleta M Zelek et al. MOLECULAR IMMUNOLOGY
- Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica
- (2019) Richard K. Burt et al. NEUROLOGY
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- (2019) Takashi Yamamura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders
- (2019) Tianjiao Duan et al. NEUROPHARMACOLOGY
- IdeS (Imlifidase)
- (2018) Bonnie E. Lonze et al. ANNALS OF SURGERY
- rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs
- (2018) Rolf Spirig et al. JOURNAL OF IMMUNOLOGY
- The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder
- (2018) Eun Bin Cho et al. NEUROLOGICAL SCIENCES
- Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica
- (2018) Lukmanee Tradtrantip et al. NEUROPHARMACOLOGY
- Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
- (2018) Georgina Flórez-Grau et al. Frontiers in Immunology
- Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
- (2018) Sophie Hillebrand et al. ACTA NEUROPATHOLOGICA
- Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
- (2018) Tianjiao Duan et al. Journal of Neuroinflammation
- Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
- (2018) Yan Wu et al. Multiple Sclerosis and Related Disorders
- A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)
- (2017) Michael Absoud et al. HEALTH TECHNOLOGY ASSESSMENT
- Remyelinating Pharmacotherapies in Multiple Sclerosis
- (2017) Riley M. Bove et al. Neurotherapeutics
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
- (2017) Peter Kiessling et al. Science Translational Medicine
- Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica
- (2017) Fumitaka Shimizu et al. Science Translational Medicine
- Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder
- (2017) Chao Zhang et al. JAMA Neurology
- Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G
- (2017) Xiaoming Yao et al. Acta Neuropathologica Communications
- Gut microbiome analysis in neuromyelitis optica reveals overabundance ofClostridium perfringens
- (2016) Bruce A. C. Cree et al. ANNALS OF NEUROLOGY
- Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs
- (2016) Carlos J. Bosques et al. AUTOIMMUNITY REVIEWS
- Therapeutic options in neuromyelitis optica spectrum disorders
- (2016) Joanna Kitley et al. Expert Review of Neurotherapeutics
- Th17 cells in neuromyelitis optica spectrum disorder: a review
- (2016) Jie Lin et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Therapeutic options in neuromyelitis optica spectrum disorders
- (2016) Joanna Kitley et al. Expert Review of Neurotherapeutics
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders
- (2016) Valentina Damato et al. JAMA Neurology
- Immunoadsorption in patients with neuromyelitis optica spectrum disorder
- (2016) Simon Faissner et al. Therapeutic Advances in Neurological Disorders
- Clobetasol promotes remyelination in a mouse model of neuromyelitis optica
- (2016) Xiaoming Yao et al. Acta Neuropathologica Communications
- Perampanel for focal epilepsy: insights from early clinical experience
- (2015) E. Trinka et al. ACTA NEUROLOGICA SCANDINAVICA
- B10 Cells Ameliorate the Progression of Lupus Nephritis by Attenuating Glomerular Endothelial Cell Injury
- (2015) Miao Yu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
- (2015) Jan D. Lünemann et al. Nature Reviews Neurology
- Challenges and opportunities in designing clinical trials for neuromyelitis optica
- (2015) B. G. Weinshenker et al. NEUROLOGY
- Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
- (2015) Harry Alexopoulos et al. Neurotherapeutics
- Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis
- (2015) Hideaki Nishihara et al. PLoS One
- Neuromyelitis optica: clinical features, immunopathogenesis and treatment
- (2014) S. Jarius et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets — Results of one year follow-up
- (2014) Natalia Marek-Trzonkowska et al. CLINICAL IMMUNOLOGY
- Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica
- (2014) Julien Ratelade et al. EXPERIMENTAL NEUROLOGY
- Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies
- (2014) Alessia Leone et al. Expert Review of Clinical Immunology
- Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59
- (2014) Hua Zhang et al. JOURNAL OF AUTOIMMUNITY
- Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
- (2014) Marios C. Papadopoulos et al. Nature Reviews Neurology
- Human Dendritic Cell Functional Specialization in Steady-State and Inflammation
- (2014) Arjan Boltjes et al. Frontiers in Immunology
- C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica
- (2013) Puay-Wah Phuan et al. ACTA NEUROPATHOLOGICA
- Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica
- (2013) Hua Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Aquaporin water channels in the nervous system
- (2013) Marios C. Papadopoulos et al. NATURE REVIEWS NEUROSCIENCE
- IL-10-producing regulatory B cells (B10 cells) in autoimmune disease
- (2013) Ioannis Kalampokis et al. ARTHRITIS RESEARCH & THERAPY
- Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody
- (2012) Lukmanee Tradtrantip et al. ANNALS OF NEUROLOGY
- Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica
- (2012) Lukmanee Tradtrantip et al. FASEB JOURNAL
- Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly
- (2012) Andrea Rossi et al. GLIA
- Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays
- (2012) Puay-Wah Phuan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin
- (2012) Dean M. Wingerchuk JOURNAL OF CLINICAL IMMUNOLOGY
- Aquaporin 4 and neuromyelitis optica
- (2012) Marios C Papadopoulos et al. LANCET NEUROLOGY
- Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis
- (2012) Chao Quan et al. Multiple Sclerosis Journal
- Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica
- (2011) Lukmanee Tradtrantip et al. ANNALS OF NEUROLOGY
- Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain
- (2011) Samira Saadoun et al. ANNALS OF NEUROLOGY
- Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
- (2011) M. Di Ianni et al. BLOOD
- Binding Affinity and Specificity of Neuromyelitis Optica Autoantibodies to Aquaporin-4 M1/M23 Isoforms and Orthogonal Arrays
- (2011) Jonathan M. Crane et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Estriol Generates Tolerogenic Dendritic Cells In Vivo That Protect against Autoimmunity
- (2011) T. L. Papenfuss et al. JOURNAL OF IMMUNOLOGY
- Sera from neuromyelitis optica patients disrupt the blood–brain barrier
- (2011) Fumitaka Shimizu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes
- (2011) S. R. Hinson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrathecal pathogenic antiâaquaporin-4 antibodies in early neuromyelitis optica
- (2009) Jeffrey L. Bennett et al. ANNALS OF NEUROLOGY
- Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
- (2008) Hideki Garren et al. ANNALS OF NEUROLOGY
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antiendothelial Cells Autoantibodies in Vasculitis-Associated Systemic Diseases
- (2008) Philippe Guilpain et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now